Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...
NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...
Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports
Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary endpoint -- wiping out billions in market value.
Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock
NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue...
/Biogen%20Inc%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Biogen has rallied the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.
Biogen revealed Phase 2 CELIA trial data that sent BIIB shares down approximately 6.4% in a single session.
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ:BIIB) concerning potential violations...